Evaluating Antidepressant Therapies: Remission as the Optimal Outcome

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 13, 2003, Pages 18-25

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DULOXETINE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

DEPRESSION; EVALUATION; HEALTH CARE COST; HUMAN; HYPERTENSION; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; PSYCHOTHERAPY; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SEROTONINERGIC TRANSMISSION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; DEPRESSIVE DISORDER; HUMANS; LONGITUDINAL STUDIES; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; RECURRENCE; RESEARCH DESIGN; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 0142043014     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland: the World Health Organization; 2001
2. Greenberg PE, Stiglin LE, Finkelstein SN, et al. Economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-419
3. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
4. Thase ME, Jindal R, Howland RH. Biological aspects of depression. In: Gotlib IH, Hammen CL, eds. Handbook of Depression. New York, NY: Guilford Press; 2002:192-218
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
7. Thase ME, Sloan DME, Kornstein SG. Remission is the critical outcome of treatment of depression. Psychopharmacol Bull 2002;36(suppl 13): 12-25
8. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(suppl 1):17-25
9. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800
10. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health and Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
11. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855
12. Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal valve. J Affect Disord 2002;72:177-184
13. Kupfer DJ, Ehlers CL. Two roads to rapid eye movement latency. Arch Gen Psychiatry 1989;46:945-948
14. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501
15. Haskett RG. The HPA axis and depressive disorders. In: Mann JJ, Kupfer DJ, eds. Biology of Depressive Disorders, Part A: A Systems Perspective. New York, NY: Plenum Press; 1993:171-188
16. Sapolsky RM. Why stress is bad for your brain. Science 1996;273:749-750
17. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989;262:914-919
18. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
19. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, pt 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619
20. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000;57:375-380
21. Hirschfeld RMA, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry 2002;51:123-133
22. Gotlib IH, Whiffen VE. Depression and marital functioning: an examination of specificity and gender differences. J Abnorm Psychol 1989;98:23-30
23. Lee CM, Gotlib IH. Maternal depression and child adjustment: a longitudinal analysis. J Abnorm Psychol 1989;98:78-85
24. Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992;14:237-247
25. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992:267:1478-1483
26. Simon G, Ormel J, Von Korff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995;152:352-357
27. Simon GE, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850-856
28. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-1825
29. Penninx BWJH, Beekman ATF, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001;58:221-227
30. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-1856
31. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001;38:199-205
32. Pohjasvaara T, Vataja R, Leppavuori A, et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol 2001;8:315-319
33. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA 1991;265:993-996
34. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078
35. Eaton WW, Armenian H, Gallo J, et al. Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care 1996;19:1097-1102
36. de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-630
37. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-942
38. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285
39. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25:464-470
40. Petitto JM, Evans DL. Depression in cancer and HIV infection: research findings and implications of effective antidepressant treatment. Depress Anxiety 1998;8(suppl 1):80-84
41. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment? Am J Psychiatry 1992;149:1046-1052
42. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
43. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
44. Simons AD, Murphy GE, Levine JL. Relapse after treatment with cognitive therapy and/or pharmacotherapy: results after one year. Arch Gen Psychiatry 1986;43:43-48
45. Evans MD, Hollon SD, DeRubeis, RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992;49:802-808
46. Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001;58:381-388
47. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(5, suppl):28-34
48. Thase ME. Relapse and recurrence of depression: an updated practical approach for prevention. In: Palmer KH, ed. Drug Treatment Issues in Depression. Auckland, New Zealand: Adis International Ltd; 2000:35-52
49. Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155:1443-1445
50. Paykel ES, Scott J, Teasdale J, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999;56:829-835
51. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
52. Persons JB, Thase ME, Crits-Cristoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry 1996;53:283-290
53. Rush AJ, Thase ME. Psychotherapies for depressive disorders: a review. In: Maj M, Sartorius N, eds. WPA Series Evidence and Experience in Psychiatry: Depressive Disorders, vol 1. Sussex, England: John Wiley & Sons Ltd; 1999:161-206
54. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015
55. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
56. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-1452
57. Anderson M. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(suppl 1):11-17
58. Thase ME, Frank E, Kornstein S, et al. Gender differences in response to treatments of depression. In: Frank E, ed. Gender and Its Effects on Psychopathology. Washington, DC: American Psychiatric Press; 2000:103-129
59. Nobler MS, Roose SP. Differential response to antidepressants in melancholic and severe depression. Psychiatr Ann 1998;28:84-88
60. Harvey AT, Rudolph RL, Preskom SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509
61. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404
62. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
63. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 2002;36(suppl 1):4-17
64. Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol 2002;17:53-58
65. Clerc G for the Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 2001;16:145-151
66. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002:63:308-315
67. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
68. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-508